An observational study in Idiopathic Hypersomnia, Mood Disorder and Bipolar Disorder, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by University Hospital, Toulouse · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Idiopathic Hypersomnia with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Idiopathic Hypersomnia · France.
Among the 18 studies in Idiopathic Hypersomnia with a site in France, this one is the only one that started in 2022, is one of 5 observational ones, and was the 5th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →10 of the 18 studies in Idiopathic Hypersomnia with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–54 · Healthy volunteers
Takeda · Sites in France, United States, Hong Kong and 3 more countries
Ages 18–70
Alkermes, Inc. · Sites in France, United States, Australia and 5 more countries
Ages 18–70
Centessa Pharmaceuticals (UK) Limited · Sites in France, United States, Canada and 2 more countries
Ages 18–65
Hospices Civils de Lyon · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 3
First in 2016; this study’s year is marked. 1 started in 2022.
This study's enrollment of 22 is below the median of 105 across 12 observational studies indexed under Idiopathic Hypersomnia.
Median enrollment 117 across the 13 interventional studies, 110 across the 5 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 1 study filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
6 of the studies in Idiopathic Hypersomnia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT06457945Hospices Civils de LyonMind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions | 2026-12-03 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 18 studies in Idiopathic Hypersomnia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of only patients with idiopathic hypersomnia. It is a rare and still poorly understood pathology. In clinical practice, we have found that the treatment and care offered were not always effective. The idea of this study to improve knowledge of this pathology by studying the demographic characteristics of patients and other co-morbidities, in particular psychiatric patients, to see if we can identify common factor to our patients and useful in their medical care. The main objective of this research is to allow a quantitative study of the demographic and psychiatric characteristics of patients with idiopathic hypersomnia.
patients with idiopathic hypersomnia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
adult patients with a diagnosis of idiopathic hypersomnia according to the International Classification of Sleep Disorders (ICSD 3) criteria and the performance of a 48-hour polysomnography at the Sleep Laboratory, between 2004 and today.
Other: respond to questionnaires by telephone
Seasonal Pattern Assessment Questionnaire (SPAQ) questionnaires and Sachs bipolarity index and Idiopathic Hypersomnia (IH) severity score
demographic characteristics
SPAQ questionnaires
Time frame: day 1
psychiatric characteristics
SACHS bipolarity index
Time frame: day 1
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2022 to primary completion in Jun 2024, 18 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →